## Claim

- 1. A polypeptide which comprises the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4, or an amino acid sequence in which from 1 to 10 amino acids are deleted, substituted and/or inserted in the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4, and which binds to Akt2.
- 2. A polypeptide consisting of the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4.
  - 3. A polynucleotide coding for the polypeptide described in claim 1 or claim 2.
  - 4. An expression vector comprising the polynucleotide described in claim 3.

20

25

- 5. A cell transformed with the expression vector described in claim 4.
  - 6. A method for screening a substance which inhibits binding of a polypeptide described in claim 1 or claim 2 or a polypeptide consisting of an amino acid sequence having a homology of 90% or more with the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4 and which binds to Akt2, with Akt2, which comprises

allowing (1) the aforementioned polypeptide or a cell expressing the aforementioned polypeptide, to contact (2) a substance to be tested,

measuring binding of said polypeptide with Akt2, and

selecting a substance which inhibits the aforementioned binding.

- 7. The screening method described in claim 6, wherein the binding inhibiting substance is an insulin resistance improving agent and/or a carbohydrate metabolism improving agent.
- 8. The screening method described in claim 6 or claim 7, wherein the step of measuring binding of (1) the polypeptide described in claim 1 or claim 2 or a polypeptide consisting of an amino acid sequence having a homology of 90% or more with the amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO:4, and which binds to Akt2, to (2) Akt2 is a step of measuring a change in Akt2 based on the change in the aforementioned binding.
- 9. A method for producing a pharmaceutical composition for insulin resistance improvement and/or carbohydrate metabolism improvement, which comprises

carrying out screening using the screening method described in claim 6 to claim 8, and

20 preparing a pharmaceutical preparation.

10

15